vs

Side-by-side financial comparison of NewtekOne, Inc. (NEWT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

NewtekOne, Inc. is the larger business by last-quarter revenue ($73.3M vs $60.1M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). NewtekOne, Inc. runs the higher net margin — 111.8% vs -92.6%, a 204.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -2.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 12.2%).

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

NEWT vs RYTM — Head-to-Head

Bigger by revenue
NEWT
NEWT
1.2× larger
NEWT
$73.3M
$60.1M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+86.5% gap
RYTM
83.8%
-2.7%
NEWT
Higher net margin
NEWT
NEWT
204.3% more per $
NEWT
111.8%
-92.6%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
12.2%
NEWT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
NEWT
NEWT
RYTM
RYTM
Revenue
$73.3M
$60.1M
Net Profit
$19.5M
$-55.6M
Gross Margin
88.1%
Operating Margin
-87.1%
Net Margin
111.8%
-92.6%
Revenue YoY
-2.7%
83.8%
Net Profit YoY
6.6%
EPS (diluted)
$0.64
$-0.83

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEWT
NEWT
RYTM
RYTM
Q1 26
$60.1M
Q4 25
$73.3M
$57.3M
Q3 25
$74.9M
$51.3M
Q2 25
$70.2M
$48.5M
Q1 25
$66.3M
$32.7M
Q4 24
$75.4M
$41.8M
Q3 24
$62.8M
$33.3M
Q2 24
$61.1M
$29.1M
Net Profit
NEWT
NEWT
RYTM
RYTM
Q1 26
$-55.6M
Q4 25
$19.5M
$-47.5M
Q3 25
$17.9M
$-52.9M
Q2 25
$13.7M
$-46.6M
Q1 25
$9.4M
$-49.5M
Q4 24
$18.3M
$-43.3M
Q3 24
$11.9M
$-43.6M
Q2 24
$10.9M
$-32.3M
Gross Margin
NEWT
NEWT
RYTM
RYTM
Q1 26
88.1%
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Operating Margin
NEWT
NEWT
RYTM
RYTM
Q1 26
-87.1%
Q4 25
-82.2%
Q3 25
-102.6%
Q2 25
-93.4%
Q1 25
-143.7%
Q4 24
-98.6%
Q3 24
-132.0%
Q2 24
-139.2%
Net Margin
NEWT
NEWT
RYTM
RYTM
Q1 26
-92.6%
Q4 25
111.8%
-83.0%
Q3 25
23.9%
-103.1%
Q2 25
19.5%
-96.1%
Q1 25
14.1%
-151.4%
Q4 24
24.3%
-103.6%
Q3 24
19.0%
-131.2%
Q2 24
17.9%
-110.9%
EPS (diluted)
NEWT
NEWT
RYTM
RYTM
Q1 26
$-0.83
Q4 25
$0.64
$-0.73
Q3 25
$0.67
$-0.82
Q2 25
$0.52
$-0.75
Q1 25
$0.35
$-0.81
Q4 24
$0.70
$-0.71
Q3 24
$0.45
$-0.73
Q2 24
$0.43
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEWT
NEWT
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$340.6M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$397.6M
$122.9M
Total Assets
$2.7B
$442.3M
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEWT
NEWT
RYTM
RYTM
Q1 26
$340.6M
Q4 25
$388.9M
Q3 25
$416.1M
Q2 25
$291.0M
Q1 25
$314.5M
Q4 24
$320.6M
Q3 24
$298.4M
Q2 24
$319.1M
Total Debt
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Stockholders' Equity
NEWT
NEWT
RYTM
RYTM
Q1 26
$122.9M
Q4 25
$397.6M
$139.1M
Q3 25
$386.7M
$148.8M
Q2 25
$312.2M
$-11.9M
Q1 25
$302.3M
$18.9M
Q4 24
$296.3M
$21.7M
Q3 24
$281.8M
$11.2M
Q2 24
$274.0M
$39.3M
Total Assets
NEWT
NEWT
RYTM
RYTM
Q1 26
$442.3M
Q4 25
$2.7B
$480.2M
Q3 25
$2.4B
$506.9M
Q2 25
$2.1B
$372.7M
Q1 25
$2.1B
$386.7M
Q4 24
$2.1B
$392.3M
Q3 24
$1.7B
$363.6M
Q2 24
$1.6B
$381.8M
Debt / Equity
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEWT
NEWT
RYTM
RYTM
Operating Cash FlowLast quarter
$-579.2M
Free Cash FlowOCF − Capex
$-579.3M
FCF MarginFCF / Revenue
-790.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
$-579.2M
$-25.4M
Q3 25
$-167.3M
$-26.6M
Q2 25
$-199.8M
$-23.3M
Q1 25
$-60.7M
$-40.4M
Q4 24
$-153.0M
$-18.8M
Q3 24
$-25.7M
$-25.2M
Q2 24
$2.9M
$-29.1M
Free Cash Flow
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
$-579.3M
Q3 25
$-167.3M
Q2 25
$-199.9M
Q1 25
$-60.7M
Q4 24
$-153.5M
Q3 24
$-25.9M
Q2 24
$2.9M
FCF Margin
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
-790.0%
Q3 25
-223.3%
Q2 25
-284.7%
Q1 25
-91.6%
Q4 24
-203.6%
Q3 24
-41.2%
Q2 24
4.7%
Capex Intensity
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
0.1%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.6%
Q3 24
0.4%
Q2 24
0.1%
Cash Conversion
NEWT
NEWT
RYTM
RYTM
Q1 26
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
-2.15×
Q2 24
0.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons